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PET-Neck late breaking abstract 
Authors: Smith A. F., Hall P. S., Hulme C., Dunn J., Rahman J. K., McConkey C., Mehanna 
H. 
Title:  Is PET-CT guided management for patients with locally advanced head and neck 
squamous cell cancer (HNSCC) cost-effective? Results from a UK non-inferiority phase III 
randomized trial.  
Background: Despite ongoing controversy, planned node dissection (ND) remains a 
common treatment strategy after radical chemoradiotherapy (CRT) for locally advanced 
nodal metastases in patients with HNSCC. Accurate detection of persistent disease using 
combined Positron Emission and Computerised Tomography (PET-CT) could reduce 
unnecessary and expensive node dissections (ND) in low-risk patients and potentially 
improve overall outcomes.  
Methods: 564 patients with N2/N3 oropharyngeal, laryngeal, oral, hypopharyngeal or occult 
HNSCC were randomized (1:1) to receive either planned ND (before or after CRT), or PET-
CT surveillance (CRT followed by PET-CT, with ND administered if incomplete response in 
the neck nodes). To accurately inform reimbursement decisions, individual patient data from 
the trial was used to assess within-trial (2-year) cost-effectiveness of PET-CT surveillance 
versus planned ND from an NHS secondary care perspective. Health benefit was measured 
using quality-adjusted life-years (QALYs) and costs are reported in 2015 GBP. Probabilistic 
analysis was conducted using bootstrap methods.  
Results: PET-CT surveillance was cost-effective over the trial period, producing an average 
per-person cost saving of £1,415 (95% CI: -607 to -2,218) and a health gain of 0.07 QALYs 
(95% CI: -0.04 to 0.19) compared to planned ND. The average cost was £12,127 (95% CI: 
11,601 to 12,686) for PET-CT surveillance vs. £13,542 (95% CI: 12,968 to 14,131) for 
planned ND; the average QALYs were 1.26 (95% CI: 1.18 to 1.34) vs. 1.19 (95% CI: 1.10 to 
1.27).  At a £20,000 per QALY threshold, the probability that PET-CT was the cheapest, 
most effective and most cost-effective strategy was 99%, 91%, and 98%, respectively. 
Expanding the analysis to include additional NHS, personal social services and societal costs 
increased the expected costs for each arm but did not alter the overall cost-effectiveness of 
PET-CT surveillance.  
Conclusions: Results of the economic evaluation indicate that PET-CT surveillance is cost-
effective over a short time horizon.  
   
